AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35979259
Drug: Saccharomyces cerevisiae
RxNorm normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces cerevisiae I-3856 (8 × 10^9 CFU daily)
Trial: 32875658
Drug: Rotigotine 3
RxNorm normalized name: ROTIGOTINE 3MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 3 mg per day for 6 weeks
Trial: 35999352
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody crizanlizumab
Trial: 39037799
Drug: Sodium-glucose cotransporter-2
RxNorm normalized name: glucose / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-glucose cotransporter-2 inhibitors
Trial: 35999352
Drug: Purinergic signaling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purinergic signaling receptor Y12 inhibitors
Trial: 34795191
Drug: Dance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance therapy based on the Satir Model and group psychological intervention
Trial: 35144974
Drug: Famotidine 80
RxNorm normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 80 mg orally three times a day for 14 days
Trial: 36273430
Drug: Multifamily therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifamily therapy (MFT) - 24 sessions in addition to treatment as usual (TAU)
Trial: 36273430
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - individual and family sessions
Trial: 32333714
Drug: Rectal hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal hydrogel spacer
Trial: 32333714
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no rectal hydrogel spacer)
Trial: 35122485
Drug: Sham-extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham-extracorporeal shock wave therapy (sham-ESWT)
Trial: 37354048
Drug: Dabigatran 75
RxNorm normalized name: dabigatran 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 75 mg
Trial: 35770540
Drug: Auricular ASP
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular ASP needles treatment
Trial: 35770540
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments (Control)
Trial: 35242730
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment (four biannual rounds)
Trial: 35242730
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment (two biannual rounds)
Trial: 33950544
Drug: Tea Tree
RxNorm normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea Tree Oil (10% solution, 5 mL)
Trial: 33950544
Drug: Alcohol (83%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (83% ethanol, 2 mL)
Trial: 33950544
Drug: Benzalkonium Chloride
RxNorm normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzalkonium Chloride (0.8 mL)
Trial: 32475274
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acid supplementation (9 g daily)
Trial: 32475274
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose powder, 9 g daily)
Trial: 34597713
Drug: PDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS with ranibizumab 100 mg/ml with fixed 24‐week refill‐exchanges (PDS Q24W)
Trial: 34597713
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5‐mg injections every 4 weeks (monthly ranibizumab)
Trial: 32381807
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1% curcumin, 1% hyaluronidase, and 0.1% triamcinolone acetonide
Trial: 32381807
Drug: Triamcinolone and
RxNorm normalized name: triamcinolone and antiseptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone and hyaluronidase mucoadhesive semisolid gel
Trial: 34797287
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise (TC) added to sodium hyaluronate treatment
Trial: 36175588
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (VPA) 60 mg/kg/day for 3 days (D1-D3) followed by oral etoposide 50 mg once daily for two weeks (D4-D17)
Trial: 36175588
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (historical control)
Trial: 34501728
Drug: Bilateral quadratus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral quadratus lumborum block type I with 24 mL 0.375% ropivacaine
Trial: 34309117
Drug: Postoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative concurrent chemoradiotherapy (POCRT)
Trial: 35491560
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluids (WIVF)
Trial: 33839450
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel oral suspension
Trial: 36002106
Drug: Conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen (fludarabine 75 mg/m2, total body irradiation 12 Gy, cyclophosphamide 120 mg/kg)
Trial: 33503193
Drug: Low-dose conjugated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose conjugated estrogen (CE) 0.3 mg
Trial: 33503193
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Raloxifene + Low-dose CE)
Trial: 32723723
Drug: ACT intervention
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT intervention via mobile phone messaging robot; twice-daily messages for 2 weeks post-surgery.
Trial: 34459077
Drug: Augmented cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented cognitive behavioral therapy (CBT) adjunctive to treatment as usual (TAU)
Trial: 35169036
Drug: Iberdomide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.3 mg every other day, 0.3 mg once daily, 0.6 mg and 0.3 mg alternating once daily, or 0.6 mg once daily)
Trial: 32819393
Drug: CAF3 (3-mg∙kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF3 (3-mg∙kg-1 of caffeine)
Trial: 32819393
Drug: CAF6 (6-mg∙kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF6 (6-mg∙kg-1 of caffeine)
Trial: 32819393
Drug: CON (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (no supplement)
Trial: 35726368
Drug: Immediate titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate titrated intravenous oxytocin infusion and early amniotomy
Trial: 34759152
Drug: Neutrophil/Lymphocyte (N/L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrophil/Lymphocyte (N/L) ratio
Trial: 33278897
Drug: Thermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal therapy
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1% twice daily
Trial: 38123875
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1% once daily
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5% twice daily
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5% once daily
Trial: 33608058
Drug: IVIg and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg and 1000 mg intravenous methylprednisolone (IVMP)
Trial: 35817336
Drug: D 0.3
RxNorm normalized name: folic acid 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D 0.3 μg·kg−1·h−1 dexmedetomidine
Trial: 35817336
Drug: D 0.4
RxNorm normalized name: ozanimod 0.46 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D 0.4 μg·kg−1·h−1 dexmedetomidine
Trial: 35817336
Drug: D 0.5
RxNorm normalized name: folic acid 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D 0.5 μg·kg−1·h−1 dexmedetomidine
Trial: 35817336
Drug: D 0.6
RxNorm normalized name: salicylic acid 0.6 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D 0.6 μg·kg−1·h−1 dexmedetomidine
Trial: 32569125
Drug: All supplements
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All supplements
Trial: 33734433
Drug: Standard-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose regimen (commencing at 25 μg)
Trial: 33734433
Drug: Low-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose regimen (commencing at 12 μg)
Trial: 32583013
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg yohimbine
Trial: 32583013
Drug: Uncontrollability groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncontrollability groups (no control over shock administration)
Trial: 85140364
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor specific for hepatitis B (TFdL-H) administered at 15-day intervals over a 6-month period
Trial: 33092320
Drug: Carn‐βA (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carn‐βA (2.5 g L‐carnosine plus 2.5 g β‐alanine)
Trial: 35078147
Drug: Standard European
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard European treatment protocol for LBP (control group)
Trial: 34637608
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg) under fasted conditions
Trial: 34637608
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg) under fed conditions (high-fat diet)
Trial: 34637608
Drug: Rivaroxaban test
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban test formulation
Trial: 34637608
Drug: Rivaroxaban reference
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban reference formulation (Xarelto)
Trial: 36174434
Drug: Curcumin +
RxNorm normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin + piperine (500 mg daily)
Trial: 32683541
Drug: Ordered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordered treatment methods based on maximum-likelihood and robust estimation
Trial: 33124927
Drug: Tic treatment
RxNorm normalized name: Detoxifying agents for antineoplastic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tic treatment
Trial: 38608694
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg daily
Trial: 32737923
Drug: Technosphere Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere Insulin (TI)
Trial: 32706953
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg twice daily)
Trial: 32706953
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg twice daily) plus Azithromycin (500 mg once daily for 7 days)
Trial: 34031865
Drug: Conventional cardiovascular
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional cardiovascular drugs (ACE inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins)
Trial: 34031865
Drug: Antithrombotics, pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotics, pulmonary vasodilators, RAAS‐related drugs, colchicine (ongoing RCTs)
Trial: 34031865
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term anti‐atherogenic therapies (statins)
Trial: 34031865
Drug: Current cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current cardiovascular drugs
Trial: 32822887
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - enoxaparin sodium 20 mg (2000 IU) twice a day for 1 week postoperatively
Trial: 32822887
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (Control group)
Trial: 32784157
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (Control)
Trial: 34573862
Drug: Fecal immunochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal immunochemical test (FIT) surveillance with annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10 µg/g
Trial: 35247964
Drug: Low-sodium (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium (3 g/d salt) + placebo
Trial: 35247964
Drug: Medium-sodium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-sodium (5 g/d salt) + spironolactone (SPL)
Trial: 35247964
Drug: Low-sodium (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium (3 g/d salt) + spironolactone (SPL)
Trial: 35167779
Drug: All sepetaprost
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All sepetaprost doses
Trial: 33559053
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 21 days starting from day 1 in each cycle in addition to platinum-based chemotherapy
Trial: 34168284
Drug: ixazomib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85)
Trial: 34463842
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab with targeted retinal photocoagulation (TRP)
Trial: 34088700
Drug: Genetically instrumented
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically instrumented higher insulin resistance (IR)
Trial: 34088700
Drug: Fasting insulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting insulin, glucose, or glycated hemoglobin
Trial: 32204742
Drug: Model-predicted optimal
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-predicted optimal treatment
Trial: 32204742
Drug: Model-predicted optimal
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-predicted optimal treatment (top 60% prediction)
Trial: 32204742
Drug: Model-predicted optimal
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-predicted optimal treatment (conservative check)
Trial: 33423837
Drug: Educational videos
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational videos about vaccines and small pharmacy-based financial incentives for vaccine receipt
Trial: 32738365
Drug: Acupressure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure therapy in combination with pharmacological treatment (n = 106)
Trial: 32738365
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment only (Control group, n = 106)
Trial: 36217659
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioral therapy (9 sessions over 8 weeks)
Trial: 36217659
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with medication and vestibular rehabilitation (control group)
Trial: 36217659
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioral therapy
Trial: 33638976
Drug: Empiric TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric TB therapy
Trial: 32096209
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of red wine oligomeric procyanidins (OPCs)
Trial: 32659699
Drug: Routine face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine face to face occupational therapy intervention (Control)
Trial: 34697783
Drug: Ulmus macrocarpa
RxNorm normalized name: Ulmus rubra pollen
DrugBank: Ulmus rubra pollen (DB10985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulmus macrocarpa Hance extract (UME) 500 mg/day for 4 weeks
Trial: 33151988
Drug: Indigo naturalis
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigo naturalis (IN) 500 mg, 5 capsules twice a day for 2 weeks
Trial: 33492301
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg/d for 12 weeks
Trial: 33317460
Drug: Oropharyngeal tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oropharyngeal tetracaine spray (Group S‐AIC)
Trial: 34407970
Drug: Nivolumab (N)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (N) 240 mg every 2 weeks
Trial: 34407970
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + Ipilimumab (N + I) 240 mg every 2 weeks + 1 mg/kg every 6 weeks
Trial: 32622900
Drug: Cancer treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer treatments with statistically significant increase in overall survival
Trial: 32622900
Drug: Cancer treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer treatments with overall survival as primary outcome
Trial: 33231029
Drug: Standard PTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PTA treatment
Trial: 33483110
Drug: Hypoventilation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoventilation therapy (TX, n = 20)
Trial: 34545117
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics administered by paramedics
Trial: 34488061
Drug: Dexmedetomidine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (intravenous 0.4 ?g/kg/h immediately after anesthesia induction and 0.1 ?g/kg/h after extubation, maintained until 24 h)
Trial: 32917645
Drug: Calcium (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1,200 mg/day)
Trial: 32917645
Drug: Calcium (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1,200 mg/day) in patients with DBP2 isoform
Trial: 34129236
Drug: Dichlorphenamide (DCP)
DrugBank: Diclofenamide (DB01144)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dichlorphenamide (DCP) 50 mg twice daily
Trial: 32711393
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training with resistive equipment (CTRE)
Trial: 32711393
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training with multiple sets (CTMS)
Trial: 32530339
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (1000 IU daily)
Trial: 36288585
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% and dexmedetomidine 1 mcg/kg
Trial: 34797324
Drug: N-butylphthalide (NBP)
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-butylphthalide (NBP) therapy
Trial: 32066898
Drug: Non-treatment visits
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment visits
Trial: 32066898
Drug: Injection visits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection visits